ImmutepASX:IMM 14-Day RSI is 53.96 as of Jul. 06, 2026. The stock has 1 warning sign investors should review. Among 1,419 Biotechnology companies, Immutep ranks worse than 59.97% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-06), Immutep's 14-Day RSI is 53.96.
The industry rank for Immutep's 14-Day RSI or its related term are showing as below:
ASX:IMM's 14-Day RSI is ranked worse than 59.97% of 1419
companies
in the Biotechnology industry
Industry Median: 50.98
vs ASX:IMM: 53.96
Immutep (ASX:IMM) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Immutep 14-Day RSI Related Terms
ASX:IMM vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Immutep's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immutep 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immutep's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Immutep's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immutep (ASX:IMM) has a 14-Day RSI of 53.96 as of Jul. 06, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Immutep and its competitors. According to the industry distribution chart, Immutep ranks #851 out of 1419 companies in the Biotechnology industry, placing it in the top 60%.
Is Immutep's 14-Day RSI too high?
Immutep's current 14-Day RSI is 53.96. The Biotechnology industry median 14-Day RSI is 50.98. Immutep's value of 53.96 is 5.8% above this industry median. Based on the distribution chart, Immutep ranks #851 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint.
How does Immutep's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #851 out of 1419 companies for 14-Day RSI. This places Immutep in the lower half of its industry. The industry median 14-Day RSI is 50.98. Immutep's value of 53.96 is 5.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 50.98, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immutep's current 14-Day RSI of 53.96 is 5.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Immutep and its competitors. For the Biotechnology industry, the median 14-Day RSI is 50.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current 14-Day RSI is 53.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (ASX:IMM) has a current 14-Day RSI of 53.96. The current 14-Day RSI is 53.96 and 5.8% above the Biotechnology industry median of 50.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Immutep (ASX:IMM), the current 14-Day RSI is 53.96 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMM has been successfully added to your